To mark World IBD Day, IHU Infiny and Afa Crohn RCH co-hosted a scientific conference highlighting two forward-looking research projects, supported by both Afa and IHU Infiny.
The event was opened by Benoît Chassaing, Fundamental and translational research Director of IHU Infiny, and Anne Buisson, Executive Director of Afa Crohn RCH, who emphasized the importance of aligning research excellence with lived patient experience to advance inflammatory bowel diseases (IBD) care.
Two presentations, two scientific angles, one shared goal: to better understand and IBD.
Microplastics and intestinal inflammation: an emerging link
Djésia Arnone (Experimental Research at IHU, NGERE – Inserm, Université de Lorraine) shared early findings suggesting that chronic exposure to microplastics could worsen intestinal inflammation.
The project, conducted with PhD candidate Claire Masi, investigates how different microplastic types affect cell viability, immune responses, and colitis severity in preclinical models.
Why does it matter This topic is still relatively new in human health research. These findings could help us understand how environmental exposure to plastics affects not just IBD patients, but digestive health more broadly, with clear implications for global and environmental health.
IBD and cardiovascular risk: looking beyond the gut
Jérémy Lagrange (CRCN, DCAC – Inserm, Université de Lorraine) explored the role of the glycocalyx, a protective endothelial layer that may deteriorate in the inflammatory environment of IBD.
His study reveals that such degradation could contribute to a higher risk of thrombosis among patients.
Why does it matter? People living with IBD face a two- to threefold increased risk of thrombotic complications. Understanding this mechanism opens the door to novel biomarkers and improved cardiovascular prevention strategies.
High translational potential
These projects reflect IHU Infiny’s mission: to connect fundamental, translational, and clinical research, turning new knowledge into concrete benefits for patients.
Special thanks to our partner Afa Crohn RCH, whose 360° commitment — funding research, supporting patients, raising awareness — makes it a driving force in the IBD ecosystem. These synergies are invaluable and reflect a shared commitment to putting patients at the heart of scientific and medical progress.
A second conference will take place on May 19 as part of our World IBD Day program.
It will focus on the latest advances in IBD management — from care pathways to innovative treatments.
Free registration
From May 17 to 23, we’ll also be present at several public information booths.
Check out our full program to find out where to meet us and learn more about inflammatory bowel diseases (IBD).
